Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ocrelizumab Proves Efficacious in MS Treatment

Ann Pharmacother; ePub 2017 Dec 12; Stahnke, et al

Ocrelizumab, a new B-cell–targeted therapy for multiple sclerosis (MS), demonstrated efficacy in the treatment of relapsing and primary progressive MS (PPMS), according to a recent literature review, and is the first therapy approved for patients with PPMS. A comprehensive literature search was conducted using search terms “ocrelizumab” and “multiple sclerosis” using the date range of 1946 through October 2017. Investigators found:

  • A phase II trial established 600 mg intravenously every 6 months as the preferred dosing schedule.
  • 2 phase III trials evaluated the efficacy of ocrelizumab in patients with relapsing remitting MS, and individual and pooled analysis demonstrated a significant reduction in annualized relapse rate, disability progression at 12 weeks, and gadolinium-enhancing lesions on magnetic resonance imaging (MRI).
  • Patients with PPMS were evaluated in a third phase III trial, which showed a significant decrease in disease progression at 12 weeks and volume of T2-weighted lesions on MRI.

Stahnke AM, Holt KM. Ocrelizumab: A new B-cell therapy for relapsing remitting and primary progressive multiple sclerosis. [Published online ahead of print December 12, 2017]. Ann Pharmacother. doi:10.1177/1060028017747635.

This Week's Must Reads

Higher Cortisol Linked with Lower Brain Volume, Neurology; ePub 2018 Oct 24; Echouffo-Tcheugui, et al

Ischemic Stroke Transfers in the Northeastern US, J Stroke Cerebrovasc Dis; ePub 2018 Oct 30; Zachrison, et al

Predictors of Recurrent Hospitalizations Post-TIA, J Stroke Cerebrovasc Dis; ePub 2018 Oct 17; Yousufuddin, et al

Sleep Apnea Associated with Less Healthful Diet, Sleep; ePub 2018 Oct 22; Reid, Maras, Shea, et al

Hypertension, Obesity, Cognitive Decline Examined , Alzheimers Dement; ePub 2018 Oct 24; Clark, et al

Must Reads in Multiple Sclerosis

No Link Between Overall Diet, MS Risk in Women, Mult Scler; ePub 2018 Oct 23; Rotstein, et al

Pubertal Onset of MS and Relapses in Boys, Mult Scler Relat Disord; ePub 2018 Oct 22; Young, et al

FLAIR Signal and Venous Abnormalities Linked in MS, AJNR Am J Neuroradiol; ePub 2018 Oct 18; Rogers, et al

Diabetes and Anxiety Affect Cognition in MS, Mult Scler Relat Disord; ePub 2018 Oct 23; Marrie, et al

Illness Intrusiveness on Intimacy in Persons with MS, Qual Life Res; 2018 ePub 2018 Oct 17; Neto, et al